Covid19 Clinical Trial
Official title:
The Burden of COVID-19 Survivorship: Exercise Therapy to Combat the Sequelae of COVID-19
| Verified date | March 2024 |
| Source | Mayo Clinic |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
This research study is being done to find out what the longer-term physiological consequences of COVID-19 are, and to determine if exercise therapy can help improve lung function, heart function and overall fitness, and reduce symptoms in people recovering from SARS-CoV-2.
| Status | Recruiting |
| Enrollment | 50 |
| Est. completion date | December 31, 2024 |
| Est. primary completion date | December 31, 2023 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 21 Years to 75 Years |
| Eligibility | Inclusion Criteria: - Aged 21 to 75 years. - History of RT-PCR proven SARS-CoV-2 infection. - Deemed 'recovered' from SARS-CoV-2 infection. - Not clinically obese (BMI = 36) and/or suffer from musculoskeletal or other conditions that would limit exercise participation. - No evidence of cardiac ischemia at rest or during exertion (via ECG). - Able to provide written informed consent. Exclusion Criteria: - Individuals less than 21 or more than 75 years old. - Not able to take part in structured exercise training due to injury or other conditions that would put person at risk during exercise. - Unable to provide written informed consent. |
| Country | Name | City | State |
|---|---|---|---|
| United States | Mayo Clinic in Florida | Jacksonville | Florida |
| Lead Sponsor | Collaborator |
|---|---|
| Mayo Clinic |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Maximal oxygen update (VO2max) measured in mL/kg/min | VO2max is the maximal oxygen consumed during an exhaustive exercise test | 8 weeks | |
| Secondary | Peak exercise work rate (Wpeak) measured in Watts | Wpeak is the highest achieved power during a maximal incremental cycle exercise test | 8 weeks | |
| Secondary | Forced vital capacity (FVC) measured in L | FVC is the largest amount of air that can be exhaled from the lungs in one maximal breath | 8 weeks | |
| Secondary | Forced expiratory volume in 1 second (FEV1) measured in L | FEV1 is the largest amount of air that can be exhaled from the lungs in the first second of one maximal breath | 8 weeks | |
| Secondary | Maximal inspiratory pressure (MIP) measured in cmH2O | Highest inspiratory muscle pressure (i.e. inspiratory muscle strength) during a maximal inspiratory effort | 8 weeks | |
| Secondary | Maximal expiratory pressure (MEP) measured in cmH2O | Highest expiratory muscle pressure (i.e. expiratory muscle strength) during a maximal expiratory effort | 8 weeks | |
| Secondary | Left ventricular contractile function measured as % fractional area change (LV FAC) | LV FAC is a measure of overall contractile function of the LV | 8 weeks | |
| Secondary | Right ventricular contractile function measured as % fractional area change (RV FAC) | RV FAC is a measure of overall contractile function of the RV | 8 weeks |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05047692 -
Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers
|
Phase 1 | |
| Recruiting |
NCT04395768 -
International ALLIANCE Study of Therapies to Prevent Progression of COVID-19
|
Phase 2 | |
| Completed |
NCT04506268 -
COVID-19 SAFE Enrollment
|
N/A | |
| Terminated |
NCT04555096 -
A Trial of GC4419 in Patients With Critical Illness Due to COVID-19
|
Phase 2 | |
| Completed |
NCT04508777 -
COVID SAFE: COVID-19 Screening Assessment for Exposure
|
||
| Completed |
NCT04961541 -
Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04546737 -
Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients
|
N/A | |
| Terminated |
NCT04581915 -
PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19
|
Phase 2/Phase 3 | |
| Terminated |
NCT04542993 -
Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy
|
Phase 2 | |
| Completed |
NCT04532294 -
Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants
|
Phase 1 | |
| Not yet recruiting |
NCT04543006 -
Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19
|
N/A | |
| Completed |
NCT04494646 -
BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)
|
Phase 2 | |
| Completed |
NCT04537663 -
Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults
|
Phase 4 | |
| Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
| Not yet recruiting |
NCT04527211 -
Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel
|
Phase 3 | |
| Completed |
NCT04387292 -
Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic
|
N/A | |
| Completed |
NCT04979858 -
Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask
|
N/A | |
| Not yet recruiting |
NCT05038449 -
Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19
|
N/A | |
| Completed |
NCT04610502 -
Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients
|
Phase 2 | |
| Active, not recruiting |
NCT06042855 -
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)
|
Phase 3 |